MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors

Area of Science:

• Oncology
• Biomedical Imaging
• Molecular Diagnostics

Background:

• Epidermal growth factor receptor (EGFR) is a key target in brain cancer therapy.
• Accurate determination of EGFR status is crucial for effective treatment selection.
• Current methods for assessing EGFR status can be invasive or lack precision.

Purpose of the Study:

• To evaluate the diagnostic potential of MRI-coupled fluorescence molecular tomography (FMT) for determining EGFR status in brain cancer.
• To assess the sensitivity and specificity of this combined imaging technique in preclinical models.

Main Methods:

• Two orthotopic glioma xenograft models with high and low EGFR expression were utilized.
• Mice were injected with a near-infrared fluorophore-conjugated epidermal growth factor (EGF) ligand.
• Animals underwent combined MRI-FMT imaging 48 hours post-injection.

Main Results:

• MRI-FMT successfully differentiated between tumors with high and low EGFR expression.
• Receiver operating characteristic analysis demonstrated 100% sensitivity and specificity.
• The technique also showed high performance in distinguishing EGFR-positive tumors from control groups.

Conclusions:

• MRI-FMT with fluorescent EGF provides excellent discrimination of tumors based on EGFR status.
• This minimally invasive approach offers reliable quantification of receptor status in research animals.
• The findings suggest potential for application in human brain cancer diagnostics and treatment monitoring.